JP2025183210A5 - - Google Patents

Info

Publication number
JP2025183210A5
JP2025183210A5 JP2025134190A JP2025134190A JP2025183210A5 JP 2025183210 A5 JP2025183210 A5 JP 2025183210A5 JP 2025134190 A JP2025134190 A JP 2025134190A JP 2025134190 A JP2025134190 A JP 2025134190A JP 2025183210 A5 JP2025183210 A5 JP 2025183210A5
Authority
JP
Japan
Prior art keywords
monoclonal antibody
use according
cells
dose
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025134190A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025183210A (ja
Filing date
Publication date
Priority claimed from JP2020505341A external-priority patent/JP7370958B2/ja
Application filed filed Critical
Publication of JP2025183210A publication Critical patent/JP2025183210A/ja
Publication of JP2025183210A5 publication Critical patent/JP2025183210A5/ja
Pending legal-status Critical Current

Links

JP2025134190A 2017-07-31 2025-08-12 血液悪性腫瘍の治療 Pending JP2025183210A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762539114P 2017-07-31 2017-07-31
US62/539,114 2017-07-31
JP2020505341A JP7370958B2 (ja) 2017-07-31 2018-07-31 血液悪性腫瘍の治療
PCT/US2018/044531 WO2019027973A1 (en) 2017-07-31 2018-07-31 TREATMENTS FOR HEMATOLOGICAL MALIGNANCY
JP2023179304A JP7728310B2 (ja) 2017-07-31 2023-10-18 血液悪性腫瘍の治療

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023179304A Division JP7728310B2 (ja) 2017-07-31 2023-10-18 血液悪性腫瘍の治療

Publications (2)

Publication Number Publication Date
JP2025183210A JP2025183210A (ja) 2025-12-16
JP2025183210A5 true JP2025183210A5 (https=) 2026-04-13

Family

ID=65233069

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020505341A Active JP7370958B2 (ja) 2017-07-31 2018-07-31 血液悪性腫瘍の治療
JP2023179304A Active JP7728310B2 (ja) 2017-07-31 2023-10-18 血液悪性腫瘍の治療
JP2025134190A Pending JP2025183210A (ja) 2017-07-31 2025-08-12 血液悪性腫瘍の治療

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020505341A Active JP7370958B2 (ja) 2017-07-31 2018-07-31 血液悪性腫瘍の治療
JP2023179304A Active JP7728310B2 (ja) 2017-07-31 2023-10-18 血液悪性腫瘍の治療

Country Status (7)

Country Link
US (1) US20200121815A1 (https=)
EP (2) EP3661557B1 (https=)
JP (3) JP7370958B2 (https=)
CN (1) CN111050796A (https=)
ES (1) ES3049118T3 (https=)
PL (1) PL3661557T3 (https=)
WO (1) WO2019027973A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12083192B2 (en) 2017-12-04 2024-09-10 Actinium Pharmaceuticals, Inc. Methods for treatment of patients with myelodysplastic syndromes
WO2020132672A1 (en) 2018-12-21 2020-06-25 Actinium Pharmaceuticals, Inc. Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancer
US20220202967A1 (en) * 2019-04-25 2022-06-30 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
CN114258401B (zh) * 2019-07-16 2025-08-12 Inserm(法国国家健康医学研究院) 对cd38具有特异性的抗体及其用途
WO2021134045A1 (en) * 2019-12-26 2021-07-01 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd38 therapeutic agent
CA3196402A1 (en) * 2020-10-22 2022-04-28 Dale L. Ludwig Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
WO2022216965A1 (en) * 2021-04-07 2022-10-13 Actinium Pharmaceuticals, Inc. Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells
WO2023045859A1 (zh) * 2021-09-23 2023-03-30 非同（成都）生物科技有限公司 Cd38单克隆抗体及其应用
WO2023109928A1 (zh) * 2021-12-16 2023-06-22 上海宝济药业有限公司 抗免疫球蛋白降解酶酶切的Fc变体
WO2024131849A1 (zh) * 2022-12-21 2024-06-27 非同（成都）生物科技有限公司 Cd38单克隆抗体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921690A (en) * 1986-12-29 1990-05-01 City Of Hope Method of enhancing the biodistribution of antibody for localization in lesions
CA2411102A1 (en) * 2000-06-20 2001-12-27 Idec Pharmaceutical Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
NZ530212A (en) 2001-06-13 2006-09-29 Genmab As An isolated human monoclonal antibody that binds to human epidermal growth factor receptor (EGFR)
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US8398956B2 (en) * 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
CA2768658C (en) * 2009-07-22 2018-04-03 Actinium Pharmaceuticals, Inc. Methods for generating radioimmunoconjugates
DK2580243T3 (da) * 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
SI2621531T1 (sl) 2010-09-27 2017-06-30 Morphosys Ag Anti-cd38 protitelo in lenalidomid ali bortezomib za zdravljenje multiplega mieloma in nhl
ES2621377T3 (es) * 2012-11-05 2017-07-03 Morphosys Ag Anticuerpo marcado radiactivamente y usos del mismo
US9120144B2 (en) * 2013-02-06 2015-09-01 Siemens Aktiengesellschaft Casting core for twisted gas turbine engine airfoil having a twisted rib
BR112015030457A2 (pt) * 2013-06-07 2017-08-22 Nordic Nanovector As Método para regular positivamente a expressão de antígeno
US9732154B2 (en) * 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
WO2020132672A1 (en) * 2018-12-21 2020-06-25 Actinium Pharmaceuticals, Inc. Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2025183210A5 (https=)
EP2593139B1 (en) Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
US11591406B2 (en) Treatment for multiple myeloma (MM)
EP3769783A1 (en) Compositions comprising anti-cd38 antibodies and carfilzomib
WO1995019769A1 (en) Combinations of a creatine compound with a hyperplastic inhibitory agent for inhibiting undesirable cell growth
EP2646033A1 (en) Volasertib alone or in combination with cytarabine for treating acute myeloid leukemia
CN102458416A (zh) 用于治疗癌症或癌前病症的交错方法
JP2021501140A (ja) リンパ球悪性疾患を治療するための方法
CN119236099A (zh) 治疗非霍奇金淋巴瘤的药物组合及其用途
JPWO2020118252A5 (https=)
JP2021063014A (ja) 白血病治療薬
KR102002581B1 (ko) 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물
WO2023244973A1 (en) Compositions and methods for reducing adverse side effects in cancer treatment
CN116509865B (zh) 硝酮类化合物在制备预防或治疗骨髓抑制药物中的应用
Petruzelka et al. Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy—results from an expanded access programme
US20190192559A1 (en) Combination of proteasome inhibitors and anti-cd30 antibodies
EP4238579A1 (en) Malignant mesothelioma therapeutic agent and malignant mesothelioma patient selection method
Shulman et al. Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: A pharmacokinetic study
WO2023227760A1 (en) Treatment of cancer with s1p receptor agonists
CN121969400A (zh) 治疗非霍奇金淋巴瘤的药物组合及其用途
WO2025261276A1 (zh) 含抗cd20抗体药物偶联物的药物组合及其治疗非霍奇金淋巴瘤的用途
CN119816307A (zh) 包含flt3抑制剂的癌症组合疗法
Douer A Woman With CD19-Positive, B-Cell ALL
JPWO2021038097A5 (https=)
HK1254083B (en) Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer